Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Myvac

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

SITC 2024

Published 7 October 2024
Categorized as 2024, dates, Myvac, Press release, TG4050

Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

A. Lalanne, et al. AACR 2024  Abstract available on the AACR website – Download the poster Poster Presentation

Published 9 April 2024
Categorized as 2024, Myvac, Publication, TG4050

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

TG4050 AACR 2024

Published 9 April 2024
Categorized as 2024, Myvac, Press release, TG4050

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

TG4050 AACR 2024

Published 6 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Transgene Nec and BostonGene expand collaboration

Published 5 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

Transgene and NEC extend their collaboration

Published 8 January 2024
Categorized as 2024, dates, Myvac, Press release, TG4050

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene and NEC present New Data on TG4050 at ASCO 2023

Published 6 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

C. Ottensmeier, et al. ASCO 2023  Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation

Published 26 May 2023
Categorized as 2023, Myvac, Publication, TG4050

Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting

Published 26 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Myvac, Press release, TG4001, TG4050

Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

A. Lalane et al.AACR 2023Download the poster herePoster Presentation

Published 18 April 2023
Categorized as 2023, Myvac, Publication, TG4050

Posts pagination

Newer posts Page 1 … Page 4 … Page 7 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu